Skip to main content
Download PDF
  • Article de Revue
  • Androgènes et Sports
  • Open access
  • Published:

The actions and side effects of Anabolic Steroids in sport and social abuse

Andrologie volume 13, pages 354–366 (2003)Cite this article

An Erratum to this article was published on 01 March 2004

Abstract

Anabolic steroids (AS) derived from testosterone have both anabolic (muscle and strength enhancing) and androgenic (primary and secondary sexual) effects. Efforts to limit the androgenic while enhancing the anabolic effects have not been successful. Alterations to the structure of testosterone, so as to improve the pharmacokinetics of AS, have resulted in drugs, which are orally active, have a longer plasma half life and may be administered as depot injections. Therapeutic doses of AS produce statistically significant effects on strength and athletic performance in well-controlled scientific and clinical trials. At low, therapeutic doses, diet and an intensive training regime are equally important in producing a statistically significant increase in strength. Higher doses 6–7000mg per week are regularly administered in sport and produce the greatest increases in muscle strength erythropoiesis and lean body mass. Patterns of steroid abuse can be complex, reflecting a desire to minimise side effects, and avoid detection. AS side effects are of many types. AS increase salt and water retention leading to an expansion of the blood volume, but effects of steroids on blood pressure are equivocal and most cardiovascular side effects appear to be reversible.

Abuse of AS causes an increase in blood triglyceride and cholesterol levels and this is associated with a decline in High Density Lipoproteins (HDLs) and an increase in the Low Density (LDL) type. Though these effects are reversible they are associated with an increased risk of both acute and chronic cardiovascular pathology. The most serious irreversible anabolic steroid side effects are associated with carcinomas-mainly of the liver, prostate and kidney. Hepatic carcinomas are strongly associated with abuse of the orally active 17alpha methyl substituted steroids, which also produce a reversible jaundice. In males, anabolic steroid abuse causes suppression of LH and FSH release leading to inhibition of testosterone production often accompanied by testicular atrophy, and azoospermia. High, chronic doses of the drugs may also cause moderate to severe feminising effects in the form of gynaecomastia. Male secondary sexual characteristics are a side effect of AS abuse in women. Increased insulin resistance and elevated fasting blood glucose levels are the commonest non-gonadal endocrine side effects of AS.

AS abuse leads to contradictory, complex, behavioural, and psychiatric changes. Increased frequency of mental illness, in anabolic steroid abusers including paranoid schizophrenia, mania and depression has been reported. Physical and psychological dependency occur amongst some anabolic steroid abusers and severe psychiatric disorders can appear upon withdrawal, leading in a few cases to criminality and even suicide. We need more studies on the long-term effects of AS. The implications of the past 50 years of AS abuse will be discussed in the review.

References

  1. ALDER E.M., COOK A., DAVIDSON D., WEST C. BANCROFT J.: Hormones, mood and sexuality in lactating women. Br. J. Psychiatry, 1986, 148: 74–79.

    Article  PubMed  CAS  Google Scholar 

  2. ALEN M., RAHKILA P.: Anabolic-androgenic steroid effects on endocrinology and lipid metabolism in athletes. Sports Med., 1988, 6: 327–332.

    Article  PubMed  CAS  Google Scholar 

  3. ARCHER J.: The influence of testosterone on human aggression. Br. J. Psychol., 1991, 82: 1–28.

    PubMed  Google Scholar 

  4. BAGATELL C.J., BREMNER W.J.: Androgens in men uses and abuses. New Engl J. Med., 1996, 334: 707–714.

    Article  PubMed  CAS  Google Scholar 

  5. BAGATELL C.J., HEIMANN J.R., RIVIER J.E.: Effects of endogenous testostrone and estradiol on sexual behaviour in normal young men. J. Clin. Endocrinol. Metab., 1994, 78: 713–716.

    Google Scholar 

  6. BAHRKE M.S.: Psychological effects of endogenous testosterone and anabolic-androgenic steroids. In: Yesalis C. ed. Anabolic Steroids in sport and exercise. Champaign Il, Human Kinetics Publishers, 2000: 94–106.

    Google Scholar 

  7. BHASIN S., STORER T.W., BERMAN N. et al.: The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl. J. Med., 1996, 335: 1–7.

    Article  PubMed  CAS  Google Scholar 

  8. BHASIN S., WOODHOUSE L., STORER T.W.: Proof of the effect of testosterone on skeletal muscle. J. Endocrinol., 2001, 170: 27–38.

    Article  PubMed  CAS  Google Scholar 

  9. BROWER K.J.: Anabolic steroids: potential for physical and psychological dependence. In: Yesalis C. ed. Anabolic steroids in sport and exercise. Champaign Il, Human Kinetics Publishers, 2000: 279–304.

    Google Scholar 

  10. BROWER K.J.: Anabolic steroid abuse and dependence. Curr. Psychiatry Reports, 2002, 4: 377–387.

    Article  Google Scholar 

  11. BROWER K.J., BLOW F.C., YOUNG J.P., HILL E.H.: Symptoms and correlates of anabolic steroid dependence. Br. J. Addict., 1991, 86: 759–768.

    Article  PubMed  CAS  Google Scholar 

  12. CHOI P.Y.L., POPE H.G.: Violence towards women and illicit androgen-anabolic steroid use. Ann. Clin. Psychiatry, 1994, 6: 21–25.

    Article  PubMed  CAS  Google Scholar 

  13. COHEN J.C., HICKMAN R.: Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J. Clin. Endocrinol. Metab., 1987, 64: 960–963.

    PubMed  CAS  Google Scholar 

  14. COPELAND J., PETERS R., DILLON P.: Anabolic-androgenic steroid dependence in a woman. Austr. N.Z. J. Psychiatry, 1998, 32: 589–591.

    Article  CAS  Google Scholar 

  15. COSTILL D.L., PEARSON D.R., FINK W.J.: Anabolic steroid use among athletes. Changes in HDC-C levels. Phys. Sports Med., 1984, 12: 113–117.

    Google Scholar 

  16. DALY R.C., SU T-P., SCHMIDT P.J., PICKAR D., MURPHY D.L., RUBINOW D.R.: Cerebrospinal fluid and behavioural changes after methyltestosterone administration. Arch. Gen. Psychiatry, 2001, 58: 172–177.

    Article  PubMed  CAS  Google Scholar 

  17. DALY R.C., SU T-P., SCHMIDT P.J., PAGLIARO M., PICKAR D., RUBINOW D.R.: Neuroendocrine and behavioural effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology, 2003, 28: 317–331.

    Article  PubMed  CAS  Google Scholar 

  18. EBENBICHLER C.F., STURM W., GANZER H. et al.: Flow-mediated, endothelium dependent vasodilation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis, 2001, 158: 483–490.

    Article  PubMed  CAS  Google Scholar 

  19. ELASHOFF J.D., JACKNOW A.D., SHAIN S.G., BRAUNSTEIN G.D.: Effects of anabolic-androgenic steroids on muscular strength. Ann. Int. Med., 1991, 115: 387–393.

    PubMed  CAS  Google Scholar 

  20. EVANS N.A.: Gym and tonic: a profile of 100 male steroid users. Br. J. Sports Med., 1997, 31: 54–58.

    Article  PubMed  CAS  Google Scholar 

  21. FORBES G.B.: The effect of anabolic steroids on lean body mass. The dose response curve. Metabolism, 1985, 34: 571–573.

    Article  PubMed  CAS  Google Scholar 

  22. FREED D.L.J., BANKS A.J., LONGSON D., BURLEY D.M.: Anabolic steroids in athletes: cross-over double blind trial in weightlifters. Br. Med. J., 1975, 2: 471–473.

    Article  PubMed  CAS  Google Scholar 

  23. FRIEDL K.E., YESALIS C.E.: Self-treatment of gynaecomastia in body builders who use anabolic steroids. Phys. Sports Med., 1989, 17: 67–79.

    Google Scholar 

  24. GEORGE A.J.: Drugs in Sport—chemists v cheats-a score draw! Chem. Rev., 4: 10–14.

  25. GEORGE A.J.: Anabolic steroids. In: Mottram D.R. ed. Drugs in Sprot 3rd Edition. London, E. & F. Spon, 2003, 138–188.

    Google Scholar 

  26. GILL G.V.: Anabolic steroid induced hypogonadism treated with human chorionic gonadotrophins. Postgrad. Med. J., 1998, 74: 45–46.

    Article  PubMed  CAS  Google Scholar 

  27. GLAZER G.: Arthrogenic effects of anabolic steroids on serum lipid levels. Arch. Int. Med., 1991, 151: 1925–1933.

    Article  CAS  Google Scholar 

  28. GOLDMAN B.: Death in the locker room: Steroids and sports. London, Century Publishing, 1984.

    Google Scholar 

  29. GUO Z., BENTEN W.P., KRUCKEN J., WUNDERLICH F.: Nongenomic testosterone calcium signalling: genomic actions in androgen receptor-free macrophages. J. Biol. Chem., 2002, 277: 29600–29607.

    Article  PubMed  CAS  Google Scholar 

  30. GUSTAVSSON G., TRASKMAN-BENDZ L., DEE HIGLEY J., WESTRIN Å.: CSF testosterone in 43 male suicide attempters. Europ. Neuropsychopharmacology, 2003, 13: 105–109.

    Article  CAS  Google Scholar 

  31. HARTGENS D., VAN STRAATEN H., FIDELDIJ S., RIETJENS G., KEIZER H.A., KUIPERS H.: Misuse of androgenic-anabolic steroids and human deltoid muscle fibers: differences between polydrug regimens and single drug administration. Europ. J. Appl. Physiol., 2002, 86: 233–239.

    Article  CAS  Google Scholar 

  32. HAUPT H.A., ROVERE G.D.: Anabolic steroids: A review of the literature. Am. J. Sports Med., 1984, 12: 469–484.

    Article  PubMed  CAS  Google Scholar 

  33. HEALD A.H., IVISON F., ANDERSON S.G., CRUICKSHANK K., LAING I., GIBSON J.M.: Significant ethnic variation in total and free testosterone concentration. Clin. Endocrinol., 2003, 58: 262–266.

    Article  CAS  Google Scholar 

  34. HERVEY G.R., KNIBBS A.V., BURKINSHAW L. et al.: Effects of methandione on the performance and body composition of man undergoing athletic training. Clin. Sci., 1981, 60: 457–461.

    PubMed  CAS  Google Scholar 

  35. HOBBS C.J., JONES R.E., PLYMATE S.R.: Nandrolone, a 19-nortestosterone, enhances insulin dependent glucose uptake in normal men. J. Endocrinol. Metab., 1996, 81: 1582–1585.

    Article  CAS  Google Scholar 

  36. HOLMA P.K.: Effects of an anabolic steroid (methandienone) on spermatogenesis. Contraception, 1979, 15: 151–162.

    Article  Google Scholar 

  37. JAROW J.P., LIPSCHULTZ L.I.: Anabolic steroid induced hypogonadotrophic hypogonadism. Am. J. Sports Med., 1990, 18: 429–431.

    Article  PubMed  CAS  Google Scholar 

  38. KADI F., ERIKSSON A., HOLMNER S., BUTLER-BROWNE G., THORNHILL L.E.: Cellullar adaptation of the trapezius muscle in strength trained athletes. Histochem. Cell Biol., 1999, 111: 189–195.

    Article  PubMed  CAS  Google Scholar 

  39. KADI F., BONNERUND P., ERIKSSON A., THORNELL L.E.: The expression of androgen receptors in human neck and limb muscles: effects of training and self-administration of androgenic-anabolic steroids. Histochem. Cell Biol., 2000, 113: 25–29.

    Article  PubMed  CAS  Google Scholar 

  40. KASHKLIN K.B., KLEBER H.D.: Hooked on hormones? An anabolic steroid addiction hypothesis. J. Amer. Med. Assoc., 1989, 262: 3166–3170.

    Article  Google Scholar 

  41. KOURI E.M., LUKAS S.E., POPE H.G., OLIVA P.S.: Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend., 1995, 40: 73–79.

    Article  PubMed  CAS  Google Scholar 

  42. KUHN C.M.: Anabolic Steroids. Endocrinol. Rev., 2002, 13: 411–434.

    Google Scholar 

  43. KUTSCHER E.C., LUND B.C., PERRY P.J.: Anabolic Steroids —A review for the clinician. Sports Med., 2002, 32: 285–296.

    Article  PubMed  Google Scholar 

  44. LUBELL A.: Does steroid abuse cause-or excuse-violence? Phys. Sport Med., 1989, 17: 176–185.

    Google Scholar 

  45. LUKAS S.E.: Current perspectives on anabolic-androgenic steroid abuse. Trends Pharmacol. Sci., 1993, 14: 61–68.

    Article  PubMed  CAS  Google Scholar 

  46. LOMBARDO J.A., HICKSON P.C., LAMB D.R.: Anabolic/androgenic steroids and growth hormone. In: Lamb D.R., Williams M.H. eds. Perspectives in Exercise Science and Sports Medicine, Vol. 4: Ergogenics-Enhancement of Performance in Exercise and Sport. New York, Brown and Benchmark, 1991, 249–278.

    Google Scholar 

  47. MCINDOE J.H., PERRY P.J., YATES W.R. et al.: Testosterone suppression of the HPT axis. J. Invest. Med., 1997, 45: 441–447.

    Google Scholar 

  48. MILLAR A.P.: Licit steroid use—hope for the future. Br. J. Sports Med., 1994, 28: 79–83.

    Article  PubMed  CAS  Google Scholar 

  49. MOTTRAM D.R., GEORGE A.J.: Anabolic steroids. Clin. Endocrinol. Metab., 2000, 14: 55–69.

    CAS  Google Scholar 

  50. NELSON K.A., WHITE J.S.: Androgen receptor CAG repeats and prostate cancer. Am. J. Epidemiol., 2002, 155: 883–890.

    Article  PubMed  Google Scholar 

  51. NIEMINEN M.S., RAMO M.P., VIITASALO M. et al.: Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Europ. Heart J., 1996, 17: 1576–1583.

    CAS  Google Scholar 

  52. OLIVARDIA R., POPE H.G., HUDSON J.L.: Muscle dysmorphia in male weightlifters: a case control study. Am. J. Psychiatry, 2000, 157: 1291–1296.

    Article  PubMed  CAS  Google Scholar 

  53. PARSINNEN M., KINJALA U., VARTIAINEN E., SARNA S., SEPPALA T.: Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int. J. Sports Med., 2000, 21: 225–227.

    Article  Google Scholar 

  54. PARSSINEN M., SEPPALA T.: Steroid use and long-term health risks in former athletes. Sports Med., 2002, 32: 83–94.

    Article  PubMed  Google Scholar 

  55. POPE H.G., KATZ D.L.: Psychiatric and medical effects of anabolic-androgenic steroid use. Arch. Gen. Psychiat., 1994, 51: 375–382.

    PubMed  CAS  Google Scholar 

  56. POPE H.G., GRUBER A.J., CHOI P., OLIVARDIA R., PHILLIPS K.A.: Muscle dysmorphia. Psychosomatics, 1997, 38: 548–557.

    PubMed  Google Scholar 

  57. POPE H.G., KOURI E.M., HUDSON J.I.: Effects of supraphysiological doses of testosterone on mood and aggressionin normal men. Arch. Gen. Psychiatry, 2000, 57: 133–140.

    Article  PubMed  CAS  Google Scholar 

  58. POPE H.G., COHANE G.H., KANAYAMA G., SIEGEL A.J., HUDSON J.I.: Testosterone gel supplementation for men with refractory depression: a randomised placebo-controlled trial. Am. J. Psychiatry (in press).

  59. PORCERELLI J.H., SANDLER B.A.: Narcissism and empathy in steroid users Ann. J. Psychiatry, 1995, 152: 1672–1674.

    CAS  Google Scholar 

  60. RABKIN J.G., WAGNER G.J., RABKIN R.: A double blind, placebo controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch. Gen. Psychiatry, 2000, 57: 141–147.

    Article  PubMed  CAS  Google Scholar 

  61. RAGLIN J.S.: Psychological factors in sport performance. Sports Med., 2001, 31: 875–890.

    Article  PubMed  CAS  Google Scholar 

  62. ROCKHOLD R.W.: Cardiovascular toxicity of anabolic steroids. Ann. Rev. Pharmac. Tox., 1993, 33: 497–520.

    Article  CAS  Google Scholar 

  63. ROGOL A.D., YESALIS C.E.: Anabolic-androgenic steroids and athletes: What are the issues? J. Endocrinol. Metab., 1992, 74: 465–469.

    Article  CAS  Google Scholar 

  64. RUBINOW D.R., SCHMIDT P.J.: Androgens, brain and behaviour. Am. J. Psychiatry, 1996, 153: 974–984.

    PubMed  CAS  Google Scholar 

  65. RYAN A.J.: Anabolic steroids are fool’s gold. Fed. Proc., 1981, 40: 2682–2688.

    PubMed  CAS  Google Scholar 

  66. SACHS B.D., LEIPHEIMER R.E.: Rapid effect of testosterone on striated muscle activity in rats. Neuroendocrinology, 1988, 48: 453–458.

    Article  PubMed  CAS  Google Scholar 

  67. SEIDMANN S.N., RABKIN J.G.: Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J. Affect. Disord., 1998, 48: 157–161.

    Article  Google Scholar 

  68. SHEFFIELD-MOORE M., URBAN R.J., WOLF S.E. et al.: Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J. Clin. Endocrinol. Metab., 1999, 84: 2705–2711.

    Article  PubMed  CAS  Google Scholar 

  69. STIMAC D., MILLI S., DINTINJANA R.D., KOVAC D., RISTI S.: Androgenic/Anabolic steroid induced toxic hepatitis. J. Clin. Gastroenterol., 2002, 35: 350–352.

    Article  PubMed  Google Scholar 

  70. STORER T.W., MAGLIANO L., WOODHOUSE L. et al.: Testosterone dose-dependently increases maximal voluntary strength and leg-power, but does not affect fatigability or specific tension. J. Endocrinol. Metab., 2003, 88: 1478–1485.

    Article  CAS  Google Scholar 

  71. STREET C., ANTONIO J., CUDLIPP D.: Androgen use by athletes: A re-evaluation of the health risks. Canad. J. Appl. Physiol., 1996, 21: 421–440.

    CAS  Google Scholar 

  72. SULLIVAN M.L., MARTINEZ C.M., GENNIS C. et al.: The cardiac toxicity of anabolic steroids. Prog. Cardiovasc. Dis., 1998, 41: 1–15.

    Article  PubMed  CAS  Google Scholar 

  73. THIBLIN I., LINDQUIST O., RAJS J.: Cause and manner of death among abusers of anabolic androgenic steroids. J. Forensic Sci., 2000, 45: 16–23.

    PubMed  CAS  Google Scholar 

  74. TUREK P.J., WILLIAMS R.H., GILLBRAUCH J.H. et al.: The reversibility of anabolic steroid induced azoospermia. J. Urol., 1995, 153: 1628–1630.

    Article  PubMed  CAS  Google Scholar 

  75. UEKI M., OKANA M.: Doping with naturally occurring steroids. J. Toxicol. Toxin. Rev., 1999, 18: 177–195.

    CAS  Google Scholar 

  76. VAN BREDA E., KEIZER H.A., KUIPERS H., WOLFFEN-BUTTEL B.H.R.: Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. Int. J. Sports Med., 2003, 24: 195–196.

    Article  PubMed  Google Scholar 

  77. WILLIAMSON P.J., YOUNG A.H.: Psychiatric effects of androgenic and anabolic-androgenic steroid abuse in men: a brief review of the literature. J. Psychopharmac., 1992, 6: 20–26.

    Article  CAS  Google Scholar 

  78. WILSON J.D.: Androgen abuse by athletes. Endocrinol. Rev., 1988, 9: 181–199.

    Article  CAS  Google Scholar 

  79. WOODHOUSE L.J., REISZ-PORSZASZ S., JAVANBAKHT M. et al.: Development of models to predict anabolic response to testosterone administration in healthy young men. Am. J. Physiol., 2003, 284: 1009–1017.

    Google Scholar 

  80. WRIGHT J.E.: Anabolic steroids and athletics. Exerc. Sport Sci. Rev., 1980, 8: 149–202.

    Article  PubMed  CAS  Google Scholar 

  81. WRIGHT F., BRICOUT V., DOUKANI A., BONGINI M.: Nandrolone et nor-stéroïdes: substances endogènes ou xénobiotiques? Sci. Sports, 2000, 15: 111–124.

    Article  Google Scholar 

  82. WROBLEWSKA A.M.: Androgenic-anabolic steroids and body dysmorphia in young men. J. Psychosom. Res., 1997, 42: 225–234.

    Article  PubMed  CAS  Google Scholar 

  83. WU F.C.W.: Endocrine agents of anabolic steroids. Clin. Chem., 1997, 43: 1289–1292.

    PubMed  CAS  Google Scholar 

  84. YANG P., JONES B.L., HENDERSON L.P.: Mechanisms of anabolic androgenic steroid modulation of alpha(1)beta(3)gamma(2L) GABAa receptors. Neuropharmacology, 2002, 43: 619–633.

    Article  PubMed  CAS  Google Scholar 

  85. YATES W.R., PERRY P.J., MACINDOE J., HOLMAN T. ELLINGRAD V.: Psychosexual effects of 3 doses of testosterone cycling in normal men. Biol. Psychiatry, 1999, 45: 254–260.

    Article  PubMed  CAS  Google Scholar 

  86. YESALIS C., COURSON S., WRIGHT J.: History of anabolic steroid use in sport and exercise. In: Yesalis C. ed. Anabolic Steroids in sport and exercise. Champaign Il, Human Kinetics Publishers, 2000: 54–56.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liverpool John Moores University, London

    Alan James George (Reader in Clinical Pharmacology & Director of Clinical Research Courses)

Authors
  1. Alan James George
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Communication au XIXo Congrès de la Société d’Andrologie de Langue Française, Genève, 12–14 decembre 2002.

An erratum to this article is available at http://dx.doi.org/10.1007/BF03035476.

Rights and permissions

Reprints and permissions

About this article

Cite this article

George, A.J. The actions and side effects of Anabolic Steroids in sport and social abuse. Androl. 13, 354–366 (2003). https://doi.org/10.1007/BF03035203

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03035203

Key Words

Basic and Clinical Andrology

ISSN: 2051-4190